Renowned drug discovery leader to guide alliance formed to improve scientific exchange in UK drug discovery community
Renowned drug discovery leader to guide alliance formed to improve scientific exchange in UK drug discovery community
York and London, UK, 5 February 2020: The European Laboratory Research & Innovation Group (ELRIG) UK and the British Pharmacological Society, today announced that Dr Ann Hayes has been selected to chair their joint steering committee. Dr Hayes will lead the committee to help ensure both organisations meet the objectives of the newly formed strategic alliance, which aims to bring new opportunities for education and networking in UK drug discovery and pharmacology.
Joint steering committee of ELRIG UK and the British Pharmacological Society
Dr Ann Hayes is a well-respected member of the drug discovery and pharmacology community with expertise in central nervous system disorders. She has co-founded three drug discovery companies, and sits on the scientific advisory boards of several others. Dr Hayes has been a trustee of the British Pharmacological Society, and chaired the industry sub-committee from 2012 to 2015. Prior to this, she spent over 20 years in senior roles at Glaxo (then Glaxo Wellcome), most recently as the Director of Discovery Portfolio. She completed her PhD in Pharmacology at the School of Pharmacy in London.
Dr Del Trezise, ELRIG UK member of the joint steering committee, said: “Dr Hayes’ experience in pharmacology and drug discovery means she is ideally placed to bring together ideas from these complementary fields, helping ELRIG UK and the British Pharmacological Society reach a broad scientific audience.”
Professor Clive Page, President Elect of the British Pharmacological Society and member of the joint steering committee, added: “We look forward to working closely with Dr Hayes to guide our strategic direction. This collaboration marks a new chapter of our history championing innovation in the life sciences and pharmacology.”
Dr Ann Hayes, Chair of the joint steering committee, commented: “I am honoured to be steering both organisations during our partnership. I will work hard with the committee to ensure we can meet our joint aims as organisations: to develop new openings for scientific exchange and collaboration, and to help drive the successful discovery and development of new medicines across the UK.”
For further information about ELRIG UK, please visit: www.elrig.org.
For further information about the British Pharmacological Society, please visit: www.bps.ac.uk.
ENDS
ELRIG UK
Sanj Kumar
Tel: +44 7860 89 29 44
Email: sanj.kumar@elrig.org
British Pharmacological Society
Harriet Myles
Tel: +44 (0) 207 239 0180
Email: harriet.myles@bps.ac.uk
Zyme Communications
Katie Odgaard
Tel: +44 (0)7787 502 947
Email: katie.odgaard@
About ELRIG UK www.elrig.org
ELRIG UK is a not-for-profit organisation, based in the UK. We are leaders in the provision of scientific meetings and conferences; bringing together academic and biopharma industry experts and thought leaders to exchange ideas and information. Our primary objective is to provide outstanding, leading edge knowledge to the life sciences community on an open access basis.
With more than 7,000 life science professionals across the UK and Europe, our members include scientists, researchers, engineers, developers and business-people within academia, industry, government organisations and private institutes.
Follow ELRIG UK on LinkedIn at ELRIG UK, and on Twitter @ELRIG_UK
About British Pharmacological Society www.bps.ac.uk
The British Pharmacological Society is a charity with a mission to promote and advance the whole spectrum of pharmacology, and leads the way in the research and application of pharmacology around the world. Connecting over 4,000 members from more than 60 countries, it is a global community at the heart of pharmacology.
Follow the British Pharmacological Society on LinkedIn at British Pharmacological Society, and on Twitter @BritPharmSoc
